Commentary
Update on extracorporeal photopheresis in heart and lung transplantation†
Marisa B. Marques,
Joseph Schwartz,
Corresponding Author
Marisa B. Marques
Department of Pathology, Division of Laboratory Medicine, University of Alabama at Birmingham, Birmingham, Alabama
Department of Pathology, Division of Laboratory Medicine, University of Alabama at Birmingham, 619 19th Street South, West Pavilion P230G, Birmingham, AL 35244Search for more papers by this authorJoseph Schwartz
Transfusion Medicine and Cellular Therapy Section, Department of Pathology and Cell Biology, Columbia University Medical Center, New York City, New York
Search for more papers by this authorMarisa B. Marques,
Joseph Schwartz,
Corresponding Author
Marisa B. Marques
Department of Pathology, Division of Laboratory Medicine, University of Alabama at Birmingham, Birmingham, Alabama
Department of Pathology, Division of Laboratory Medicine, University of Alabama at Birmingham, 619 19th Street South, West Pavilion P230G, Birmingham, AL 35244Search for more papers by this authorJoseph Schwartz
Transfusion Medicine and Cellular Therapy Section, Department of Pathology and Cell Biology, Columbia University Medical Center, New York City, New York
Search for more papers by this author†
From the Proceedings of the 31st Annual Meeting of the American Society for Apheresis, May 26–29, 2010, New Orleans, LA.
Abstract
Transplant rejection of solid organs remains a threat to thousands of patients despite modern immunosuppressive regimens. The currently available drugs are associated with severe complications such as hypertension, diabetes mellitus, renal failure, risk of infections, and malignancies among many others and, often enough, still allow episodes of rejection. New and less-toxic immunologic measures are desperately needed to accomplish the desired tolerance to the transplant without the undesirable side effects. Extracorporeal photopheresis (ECP) has been shown to benefit especially patients with cardiac transplants, but also those who received lung allografts. ECP likely modulates the recipient's antigen-specific immune responses and inflammation in transplantation by in vivo generation of apoptotic leukocytes. This review will highlight the need for ECP, how it is thought to act, and the published evidence for its role in cardiac and pulmonary transplantation. J. Clin. Apheresis, 2011. © 2010 Wiley-Liss, Inc.
References
- 1 Taylor DO,Stehlik J,Edwards LB,Aurora P,Christie JD,Dobbels F,Kirk R,Kucheryavaya AY,Rahmel AO,Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty sixth official adult heart transplant report—2009. J Heart Lung Transplant 2009; 28: 1007–1022.
- 2 Christie JD,Edwards LB,Aurora P,Dobbels F,Kirk R,Rahmel AO,Stehlik J,Taylor DO,Kucheryavaya AY,Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult lung and heart-lung transplantation report—2009. J Heart Lung Transplant 2009; 28: 1031–1049.
- 3 Arcasoy SM. Editorial introduction: current status of lung transplantation. Curr Opin Organ Transplant 2009; 14: 463–465.
- 4 McCurry KR,Shearon TH,Edwards LB,Chan KM,Sweet SC,Valapour M,Yusen R,Murray S. Lung transplantation in the United States, 1998–2007. Am J Transplant 2009; 9: 942–958.
- 5 Mueller NJ. New immunosuppressive strategies and the risk of infection. Transpl Infect Dis 2008; 10: 379–384.
- 6 Zafar SY,Howell DN,Gockerman JP. Malignancy after solid organ transplantation: an overview. Oncologist 2008; 13: 769–778.
- 7 Golshayan D,Pascual M. Tolerance-inducing immunosuppressive strategies in clinical transplantation: an overview. Drugs 2008; 68: 2113–2130.
- 8 Szczepiorkowski ZM,Winters JL,Bandarenko N,Kim HC,Linenberger ML,Marques MB,Sarode R,Schwartz J,Weinstein R,Shaz BH; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25: 83–177.
- 9 Khan UA,Williams SG,Fildes JE,Shaw SM. The pathophysiology of chronic graft failure in the cardiac transplant patient. Am J Transplant 2009; 9: 2211–2216.
- 10 Morelli AE,Larregina AT. Apoptotic cell-based therapies against transplant rejection: role of recipient's dendritic cells. Apoptosis 2010; 15: 1083–1097.
- 11 Hivelin M,Siemionow M,Grimbert P,Lantieri L. Extracorporeal photopheresis: from solid organs to face transplantation. Transpl Immunol 2009; 21: 117–128.
- 12 Lamioni A,Parisi F,Isacchi G,Giorda E,Di Cesare S,Landolfo A,Cenci F,Bottazzo GF,Carsetti R. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005; 79: 846–850.
- 13 Meloni F,Cascina A,Miserere S,Perotti C,Vitulo P,Fietta AM. Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients. Transplant Proc 2007; 39: 213–217.
- 14 Lamioni A,Carsetti R,Legato A,Landolfo A,Isacchi G,Emma F,Bottazzo GF,Dello Strologo L. Induction of regulatory T cells after prophylactic treatment with photopheresis in renal transplant recipients. Transplantation 2007; 83: 1393–1396.
- 15 Di Biaso I,Di Maio L,Bugarin C,Gaipa G,Dander E,Balduzzi A,Parma M,D'Amico G,Perseghin P,Biondi A,Biagi E. Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Transplantation 2009; 87: 1422–1425.
- 16 Schmitt S,Johnson TS,Karakhanova S,Naher H,Mahnke K,Enk AH. Extracorporeal photopheresis augments function of CD4+ CD25+ FoxP3+ regulatory T cells by triggering adenosine production. Transplantation 2009; 15: 411–416.
- 17 Edelson R,Berger C,Gasparro F,Jegasothy B,Heald P,Wintroub B,Vonderheid E,Knobler R,Wolff K,Plewig G,McKierman G,Christiansen I,Oster M,Honigsman H,Wilford H,Kokoschka E,Rehle T,Perez M,Stingl G,La Roche L. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987; 316: 297–303.
- 18 Perez M,Edelson R,Laroche L,Berger C. Inhibition of antiskin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes. J Invest Dermatol 1989; 92: 669–676.
- 19 Pepino P,Berger CL,Fuzesi L,Panza A,Pierson RN,Gutierrez C,Marboe CC,Smith CR,Reemtsma K,Rose EA. Primate cardiac allo- and xeno-transplantation: modulation of the immune response with photochemotherapy. Eur Surg Res 1989; 21: 105–113.
- 20 Barr ML,Meiser BM,Eisen HJ,Roberts RF,Livi U,Dall'Amico R,Dorent R,Rogers JG,Radovancevic B,Taylor DO,Jeevanandam V,Marboe CC. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998; 339: 1744–1751.
- 21 Barr ML,Baker CJ,Schenkel FA,McLaughlin SN,Stouch BC,Starnes VA,Rose EA. Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation. Clin Transplant 2000; 14: 162–166.
- 22 Dall'Amico R,Livi U,Milano A,Montini G,Andreetta B,Murer L,Zacchello G,Thiene G,Casarotto D,Zacchello F. Extracorporeal photochemotherapy as adjuvant treatment of heart transplant recipients with recurrent rejection. Transplantation 1995; 60: 45–49.
- 23 Dall'Amico R,Montini G,Murer L,Andreetta B,Zacchello G,Gambino A,Feltrin G,Caforio A,Tursi V,Livi U. Extracorporeal photochemotherapy after cardiac transplantation: a new therapeutic approach to allograft rejection. Int J Artif Organ 2000; 23: 49–54.
- 24 Kirklin JK,Brown RN,Huang ST,Naftel DC,Hubbard SM,Rayburn BK,McGiffin DC,Bourge RB,Benza RL,Tallaj JA,Pinderski LJ,Pamboukian SV,George JF,Marques M. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant 2006; 25: 283–288.
- 25 Andreu G,Achkar A,Couetil JP,Guillemain R,Heshmati F,Amrein C,Chevalier P,Guinvarch A,Dore MF,Capron F,Laaban JP,Carpantier A. Extracorporeal photochemotherapy treatment for acute lung rejection episode. J Heart Lung Transplant 1995; 14: 793–796.
- 26 Slovis BS,Loyd JE,King LEJr. Photopheresis for chronic rejection of lung allografts. N Engl J Med 1995; 332: 962.
- 27 O'Hagan AR,Stillwell PC,Arroliga A,Koo A. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest 1999; 115: 1459–1462.
- 28 Salerno CT,Park SJ,Kreykes NS,Kulick DM,Savik K,Hertz MI,Bolman RM3rd. Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis. J Thorac Cardiovasc Surg 1999; 117: 1063–1069.
- 29 Villanueva J,Bhorade SM,Robinson JA,Husain AN,Garrity ERJr. Extracorporeal photopheresis for the treatment of lung allograft rejection. Ann Transplant 2000; 5: 44–47.
- 30 Benden C,Speich R,Hofbauer GF,Irani S,Eich-Wanger C,Russi EW,Weder W,Boehler A. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation 2008; 86: 1625–1627.
- 31 Morrell MR,Despotis GJ,Lublin DM,Patterson GA,Trulock EP,Hachem RR. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J heart Lung Transplant 2010; 29: 424–431.
- 32 Astor TL,Weill D. Extracorporeal photopheresis in lung transplantation. J Cutan Med Surg 2003; 7: 20–24.
- 33 George JF,Gooden CW,Guo L,Kirklin JK. Role for CD4(+)CD25(+) T cells in inhibition of graft rejection by extracorporeal photopheresis. J Heart Lung Transplant 2008; 27: 616–622.
Citing Literature
